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RESUMEN
El coronavirus 2019 (SARS-CoV-2) ha sido declarado una emergencia de salud pública de impacto in-
ternacional por la Organización Mundial de la Salud. Debido a la aparición repentina de este proceso 
pandémico asociado con alta morbilidad y la mortalidad en todo el mundo, se han implementado varios 
tratamientos en los pacientes aquejados con esta dolencia. En este marco, comenzaron a usarse en pa-
cientes críticos altas dosis de vitamina C.
En este trabajo, analizamos los ensayos clínicos y / o trabajos de investigación disponibles en la literatu-
ra. Aunque se necesita más evidencia sobre su efectividad, es importante que el especialista comprenda 
la lógica clínica de este uso para determinar si es correcto como tratamiento concomitante.
Conclusiones: El uso de altas dosis de vitamina C por vía parenteral parece ser una alternativa segura, 
disponible y económica, especialmente para pacientes críticos.
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ABSTRACT
The 2019 coronavirus (SARS-CoV-2) has been declared a public health emergency of international con-
cern by the World Health Organization. Due to the sudden appearance of this pandemic process associ-
ated with increasing morbidity and mortality worldwide, various treatments have been implemented. In 
this framework, high doses of vitamin C began to be used in critically ill patients.
We analyze the clinical trials and/or research papers available in the literature. Although more evidence 
on its effectiveness is needed is important for the specialist to understand the clinical logic of this use to 
determine if it is correct as a concomitant treatment.
Conclusions: It seems that using high doses of vitamin C parenterally is a safe, available and economical 
alternative especially for critically ill patients.
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INTRODUCTION
SARS (Severe Acute Respiratory Syndrome) coronavirus (SARS-CoV) is a virus identified 
in 2003. SARS-CoV is thought to be an animal virus from an as-yet-uncertain animal reser-
voir, perhaps bats, that spread to other animals (civet cats) and first infected humans in the 
Guangdong province of southern China in 2002(1). The 2019 novel coronavirus (SARS-CoV-2) 
epidemic, which was first reported in December 2019 in Wuhan, China, and has been de-
clared a public health emergency of international concern by the World Health Organiza-
tion, may progress to a pandemic associated with substantial morbidity and mortality(2). This 
novel coronavirus was officially named as Corona Virus Disease 2019 (COVID-19) by WHO. 
Due to the sudden appearance of this pandemic process, various treatments have been im-
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plemented using antivirals, antibiotics, antimalarials, corti-
costeroids, etc.(3). On an almost empirical basis, high doses 
of vitamin C began to be used in critically ill patients so it 
is important for specialist to understand the clinical logic of 
this use in order to determine if it is correct as a concomi-
tant treatment.
Vitamin C or ascorbic acid (AA) is the main non-enzymat-
ic, water-soluble antioxidant present in plasma(4). The main 
functions of vitamin C are neutralizing free radicals, reduc-
ing iron, regenerating vitamin E and acting as a cofactor 
of α-ketoglutarate enzymes dioxygenases. These enzymes 
participate in the synthesis of neurotransmitters, in the reg-
ulation of gene expression and in the crosslinking of colla-
gen fibers(5).
Vitamin C works in the human body as a free radical scav-
enger, and for this reason, it prevents cell damage induced 
by free radicals(6), providing protection against various 
disorders such as arthritis, atherosclerosis, cancer, diabe-
tes, and ischemia, among others, that involve oxidative 
stress(7,8).
As it is well known, this vitamin must be incorporated into 
the diet and supplemented in many cases to achieve all its 
beneficial effects for health(9).
The absorption of vitamin C from the diet depends on a 
multiplicity of factors that depend on the facilitated diffu-
sion and on a substrate transport mechanism that involves 
the specific transporters of ascorbates, whose saturation 
and low expression control the effectiveness of serum vita-
min C concentration.
In this context, a large number of formulations containing 
ascorbic acid are available for the oral route, but when high 
doses are required, parenteral administrations are required. 
It is known that plasma vitamin C concentrations are usual-
ly below normal in critically ill patients(10), inversely corre-
lating with multi-organ failure(11), and directly with surviv-
al rates(12), which highlights the importance of this vitamin 
in the treatment and progress of this type of patient(13).
It is estimated that 40% of critically ill patients with sep-
tic shock have serum vitamin C levels that suggest scur-
vy (<11.3 μmol/l). Since vitamin C is an essential element 
in the generation of endogenous vasopressors and also a 
potential mediator in maintaining the response capacity of 
vascular vasopressors, an acute deficiency can contribute to 
hypotension, exaggerated inflammation, capillary leak and 
microcirculatory compromise(14).
Vitamin C may also function as a weak antihistamine agent 
to provide relief from flu-like symptoms such as sneezing, 
a running or stuffy nose, and swollen sinuses. Three human 
controlled trials have reported that there was significantly 
lower incidence of pneumonia in vitamin C-supplemented 
groups, suggesting that vitamin C might reduce the suscep-
tibility to lower respiratory tract infections under certain 
conditions. COVID-19 has been reported to cause lower 
respiratory tract infection, so vitamin C could be one of the 
effective choices for the treatment of COVID-19(15).
MATERIAL AND METHODS
To understand these assumptions in detail, we analyze the 
clinical trials and/or research papers available in the liter-
ature.
The search strategy was based on the combination of terms 
Mesh (Medical Subject Headings) and keywords related to 
each term, combined by the boolean operators AND, OR 
and NOT.
The keywords of interest used to identify terms were “Virus 
Diseases”; “Respiratory Insufficiency”; “Viremia”; “Pneu-
monia”; “coronavirus”; “COVID”; “Sepsis”; “Ascorbic 
Acid” ; “Vitamins [Pharmacological Action]”. Also, the ad-
ditional requirement that the articles correspond to clinical 
studies, or reviews thereof, was taken into account. There-
fore, terms and keywords related to them were introduced.
The databases consulted for the identification of the stud-
ies were: Pubmed (www.ncbi.nlm.nih.gov ) and SCOPUS 
(www.scopus.com). The strategies were complemented by 
searches of the registry for clinical trials (clinicaltrials.gov).
RESULTS AND DISCUSSION
Regarding the adverse effects that this therapy can poten-
tially bring, there are antecedents of several studies in which 
patients with respiratory pathologies were randomized to 
receive intravenous infusion of vitamin C (50 mg/kg in 5% 
dextrose in water, n=84/day), there were no study-related 
unexpected adverse events during the trial(16).
In a phase I safety trial of intravenous ascorbic acid in pa-
tients with severe sepsis, no patient on low- or high-dose 
of ascorbic acid treated suffered any identifiable adverse 
events(17). Dosing protocols for this trial emerged from 
the preclinical research. Subjects were assigned to any of 
three dosing groups (0 mg/kg/day, 50 mg/kg/day, or 200 
mg/kg/day) in a 1:1:1 ratio using a randomized scheme 
generated by using Research Randomizer(18). Nathens et 
al. administered 1 gram of ascorbic acid every 8 hours for 
28 days to critically ill patients without adverse effects(19). 
Tanaka et al. administered 66 mg/kg/hour for 24 hours to 
patients with burns on 50% of the surface area without ad-
verse events(20). Hoffer et al. administered up to 90 grams of 
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ascorbic acid intravenously 3 times a week to patients with 
advanced malignancy without adverse events(21).
However, renal failure following treatment with ascorbic 
acid has been reported in another study in patients with 
pre-existing renal disorders(22). A phase I clinical trial evalu-
ated the safety of combining high-dose intravenous ascor-
bate with gemcitabine in patients with stage IV pancreatic 
cancer. The patients tolerated the combination therapy well 
and no significant adverse effects were reported(23).
In general, high intravenous doses of ascorbic acid, even 
associated with malignant tumors, were well tolerated in 
clinical trials(24,25).
In terms of effectiveness, vitamin C has been studied in 
a variety of dosage regimens (25-200 mg/kg/day IV) for 
different critical clinical conditions including sepsis, burns, 
trauma and acute respiratory distress syndrome (ARDS)(26).
Evidence suggests that vitamin C administration may re-
duce the need for vasopressor support(27), shorten the du-
ration of mechanical ventilation(28), and the length of stay 
in the ICU(29).
Regarding the treatment of sepsis, until 2019, the quality 
and quantity of evidence was still insufficient to draw firm 
conclusions(30). In October of last year, the largest completed 
trial on vitamin C as a treatment for sepsis was published(16). 
The CITRIS-ALI trial was a double-blind, controlled, mul-
ticenter trial, enrolling 167 patients with sepsis and ARDS 
who were randomized to receive 50 mg/kg every 6 h of 
high dose intravenous vitamin C (HDIVC) for 4 days ver-
sus placebo.
Although it was a secondary result, the study showed a sta-
tistically significant difference in all-cause mortality at 28 
days (29.8% in the HDIVC group vs 46.3% in the placebo 
group, p value <0.05). The Kaplan-Meier survival curves 
for the 2 groups were significantly different using the Wil-
coxon test (χ21 = 6.5; p = 0.01). Furthermore, the group 
treated with vitamin C showed more ICU-free days at day 
28 (10.7, HDIVC vs. 7.7, placebo, p = 0.03), more days with-
out hospitalization (22.6 HDIVC vs. 15.5 placebo, p = 0.04) 
and more days without ventilator (13.1 HDIVC vs. 10.6 
placebo, p = 0.15). In view of this results and because of 
the emergency of SARS-CoV-2, the Arnas Civico- di Cristi-
na-Benfratelli National Relevance Hospital in Palermo, has 
decided to treat patients with 10 grams of vitamin C in 250 
ml of saline to infuse at a rate of 60 drops/minute(31). The 
clinical evolution of the included patients (who signed an 
informed consent) will be recorded as part of a longitudinal 
study.
Considering that the high doses of vitamin C are of neg-
ligible cost and that they have not shown any significant 
side effect, any decrease in days of hospitalization, ICU and 
mortality, makes its exploration worthwhile.
In a pandemic context such as the current one, it is impor-
tant to use the evidence to achieve appropriate and useful 
therapies. Recently, the information on the use of different 
medications for the treatment of COVID-19 has been in-
creasing quickly.
CONCLUSION
Although more evidence on its effectiveness is needed, it 
seems that using high doses of vitamin C parenterally is 
a safe, available and economical alternative especially for 
critically ill patients.
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